52
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBRT, the prognosis of this patient group is poor. We aimed to establish whether WBRT could be omitted without a significant effect on survival or quality of life.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

          Estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012 are now available in the GLOBOCAN series of the International Agency for Research on Cancer. We review the sources and methods used in compiling the national cancer incidence and mortality estimates, and briefly describe the key results by cancer site and in 20 large "areas" of the world. Overall, there were 14.1 million new cases and 8.2 million deaths in 2012. The most commonly diagnosed cancers were lung (1.82 million), breast (1.67 million), and colorectal (1.36 million); the most common causes of cancer death were lung cancer (1.6 million deaths), liver cancer (745,000 deaths), and stomach cancer (723,000 deaths). © 2014 UICC.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            EuroQol - a new facility for the measurement of health-related quality of life

            (1990)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              EuroQol--a new facility for the measurement of health-related quality of life.

              (1990)
              In the course of developing a standardised, non-disease-specific instrument for describing and valuing health states (based on the items in Table 1), the EuroQol Group (whose members are listed in the Appendix) conducted postal surveys in England, The Netherlands and Sweden which indicate a striking similarity in the relative valuations attached to 14 different health states. The data were collected using a visual analogue scale similar to a thermometer. The EuroQol instrument is intended to complement other quality-of-life measures and to facilitate the collection of a common data set for reference purposes. Others interested in participating in the extension of this work are invited to contact the EuroQol Group.
                Bookmark

                Author and article information

                Journal
                Lancet
                Lancet (London, England)
                Elsevier BV
                1474-547X
                0140-6736
                Oct 22 2016
                : 388
                : 10055
                Affiliations
                [1 ] Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
                [2 ] Medical Research Council Clinical Trials Unit at University College London, London, UK.
                [3 ] Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Hull, UK.
                [4 ] Institute of Cancer Sciences, The University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, UK.
                [5 ] Bristol Haematology and Oncology Centre, Bristol, UK.
                [6 ] Newcastle Clinical Trials Unit and Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
                [7 ] Wales Cancer Research Network, Cardiff UK.
                [8 ] The Beatson West of Scotland Cancer Centre, Greater Glasgow Health Board and Clyde, Glasgow, UK.
                [9 ] Patient representative, Manchester, UK.
                [10 ] Trans Tasman Radiation Oncology Group, Waratah, NSW, Australia; University of Queensland, QLD, Australia.
                [11 ] Nottingham University Hospital, Nottingham, UK.
                [12 ] Weston Park Hospital, Sheffield, UK.
                [13 ] Queen Elizabeth Hospital, Kings Lynn, UK.
                [14 ] Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: ruth.langley@ucl.ac.uk.
                Article
                S0140-6736(16)30825-X
                10.1016/S0140-6736(16)30825-X
                5082599
                27604504
                d1d87495-1cb8-46be-a4f4-487ffa29a056
                Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.
                History

                Comments

                Comment on this article